Author

DaBee Jeon

Observed names: Da Bee Jeon, Dabee Jeon, Jeon, DaBee

Institution: Celltrion (South Korea)

Observed institution: Celltrion (South Korea)

ORCID: 0009-0003-8484-1922

Observed ORCID: 0009-0003-8484-1922

OpenAlex ID: A5079638479

Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection

2021 · Jin Yong Kim, Young Rock Jang, et al. · Clinical Therapeutics · 48

Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study

2023 · Kim A. Papp, Mark G. Lebwohl, et al. · BioDrugs · 33

Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness

2021 · Jae Hee Cheon, Seongsu Nah, et al. · Advances in Therapy · 20

Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study

2023 · Kyung-Sang Yu, Byungwook Kim, et al. · Expert Opinion on Investigational Drugs · 13

Pharmacokinetics and Safety of CT-P17 (40 mg/0.4 ml) Versus Reference Adalimumab: Randomized Study in Healthy Japanese Adults

2023 · Miwa Haranaka, Takanori Tanaka, et al. · Immunotherapy · 10

Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study

2025 · Mark G. Lebwohl, John Y. Koo, et al. · Advances in Therapy · 7

Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study

2025 · Gerd Burmester, Piotr Adrian Klimiuk, et al. · Expert Review of Clinical Immunology · 4

Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study

2024 · Kyung-Sang Yu, Hyunwook Ryu, et al. · Expert Opinion on Biological Therapy · 4

Efficacy and Safety of CT‐P43, a Candidate Ustekinumab Biosimilar, in Moderate‐to‐Severe Plaque Psoriasis: 52‐Week Results From a Randomised, Active‐Controlled, Double‐Blind, Phase III Study

2026 · Kim A. Papp, Janusz Jaworski, et al. · Dermatologic Therapy

Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study

2025 · Mark G. Lebwohl, John Y. Koo, et al. · Advances in Therapy

Works count: 14

Citation count: 139

H-index: 6

I10-index: 5